A randomized controlled trial involving 477 patients with resected head and neck squamous cell carcinoma assessed the efficacy of an adjuvant mistletoe extract treatment. The study found no significant improvement in disease-free survival, with a hazard ratio of 0.959 (95% CI 0.725–1.268), and no differences in immune response or quality
